Navigation Links
Janssen Pharmaceutical Companies of Johnson & Johnson Submit Citizen Petition to the U.S. FDA Regarding Naming of Biosimilars
Date:1/8/2014

WASHINGTON, Jan. 8, 2014 /PRNewswire-USNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today submitted a Citizen Petition to the U.S. Food and Drug Administration (FDA) asking the agency to require biosimilars to bear nonproprietary names that are similar to, but not the same as, those of their reference products or of other biosimilars. The Petition states that distinguishable names are essential for enhancing patient safety and to ensure effective pharmacovigilance. 

"Ensuring biosimilars bear distinguishable names is of critical importance for patient safety," said Jay P. Siegel, M.D., Chief Biotechnology Officer and Head, Scientific Strategy and Policy, Johnson & Johnson.  "Names that are similar but not the same will appropriately reflect the legal and scientific reality that biosimilars are similar to but not the same as their reference products or other biosimilars."   

As FDA continues to implement the Biologics Price Competition and Innovation Act, the question of how biosimilars will be named must be addressed.  This question is currently being evaluated and will be addressed by the World Health Organization (WHO) and health authorities around the world.  Janssen submitted its Citizen Petition to communicate the company's position that requiring distinguishable names for biosimilars is critical for the safety of patients globally.

According to the Janssen Citizen Petition, the naming of biosimilars could have important patient safety implications beyond the name itself, including pharmacovigilance, product switching and extrapolation of indications.  Patients, their physicians and regulatory authorities such as the FDA need to know precisely which biological product has been used to
'/>"/>

SOURCE The Janssen Pharmaceutical Companies of Johnson & Johnson
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
10. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
11. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)...  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management ... and Regeneron will host an IR Thematic Conference Call on Alirocumab ... 2014 , Baird 2014 Healthcare Conference at 4:05 ... , Citi,s 9 th Annual Biotech Conference at ... , Morgan Stanley Global Healthcare Conference at 8:45 ...
(Date:8/19/2014)... Luoxis Diagnostics, Inc. , a ... MKT: AMPE), today announced an upcoming presentation at ... American Academy of Surgical Trauma (AAST) and Clinical ... Philadelphia, Pennsylvania that will be held ... from a recently completed five-year prospective clinical trial ...
(Date:8/19/2014)... ALBANY, New York , August 19, 2014 /PRNewswire/ ... " Surgical Navigation Systems Market (Neurosurgical Navigation Systems, ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 ... valued at USD 218.5 million in 2013 and is ... 2014 to 2020, to reach an estimated value of ...
Breaking Medicine Technology:Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 2Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 3Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 4Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 5Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 6Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 7Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 8Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 9
(Date:8/20/2014)... (PRWEB) August 20, 2014 Mixberry Media ... speech-enable their websites and create a new source of ... consume content by listening to a narration of their ... reader genders and languages. Users can now multitask: ... social networks, while consuming content. , Mixberry ...
(Date:8/20/2014)... Tappahannock, Va. (PRWEB) August 20, 2014 ... Dr. William Dameron , who joined its Warsaw Medical ... additional physician specialized in Family Medicine, is accepting new ... University School of Medicine, completed his residency at the ... relocating back to Virginia. , “I really like the ...
(Date:8/19/2014)... As moms and dads prepare their children to go ... normal routine of dropping their little ones off at daycare ... encourages them to use the opportunity to implement a ... Yarker explains, “Kids have small tummies, short attention spans, and ... food handouts, use snack time as another daily opportunity to ...
(Date:8/19/2014)... 2014 Crosley Law Firm, PC has reached ... against Lone Star Bakery for an undisclosed amount. The two ... and May of 2011, respectively. The injuries were caused by ... severe injury to the left hand of each man. , ... Bakery was short-staffed, having lost 200 of its, 500 workers ...
(Date:8/19/2014)... An editorial published in this week,s JAMA ... assessment tools when considering how to treat patients. Written ... Medical Center and chair of pediatrics at Boston University ... JAMA , the editorial examines results of a ... as an example of how doctors can often over-emphasize ...
Breaking Medicine News(10 mins):Health News:Mixberry Media, First To Offer Article Voice Narration with Integrated Audio Advertising 2Health News:Riverside Warsaw Medical Arts’ Dr. William Dameron Accepting New Patients 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 3Health News:Crosley Law Firm Reaches Settlement for Hand Amputation Victims at Commercial Bakery 2Health News:Review of clinical treatment of bronchiolitis in infants reveals over-reliance on one test 2
... Rating ... , ... (PRWEB) March 23, 2010 -- The Hartville Group Inc., which provides pet health insurance ... Insurance, Hartville Pet Insurance, and the Petshealth Care Plan, has received an A+ rating ...
... ... ... Sir Richard Bowlby keynotes ,Linking Forces, educational event with 16-year history in community , ... , ...
... , March 23 InterMune, Inc. (Nasdaq: ... (MAA), submitted on March 2 seeking approval of ... adults, was validated by the European Medicines Agency (EMA). Validation ... is complete and that the review process will begin on ...
... ... for Haiti survivors. , ... (PRWEB) March 23, 2010 -- Just like any other business, non-profit organizations must ... VoiceNation,s call center agents and auto attendants assist to fill the ...
... ... sustainable solution to the crisis in Haiti. The flexibility of these products can easily make ... ... -- Bosoley Solar Energy’s line of solar lights brings vital illumination to residents and aid ...
... ... than first thought. , ... -- Long known for being an excellent source of fiber, two recent studies suggest that apples ... antioxidants, previous research has suggested that apples may prevent or reduce the risks of certain types ...
Cached Medicine News:Health News:Pet Insurance Provider Hartville Group Gets A+ Rating From Better Business Bureau 2Health News:Pet Insurance Provider Hartville Group Gets A+ Rating From Better Business Bureau 3Health News:Children's Mental Health Conference Brings Together Top Research, Professionals, Parents and Community Agencies, April 8-9 in Miami 2Health News:Children's Mental Health Conference Brings Together Top Research, Professionals, Parents and Community Agencies, April 8-9 in Miami 3Health News:Children's Mental Health Conference Brings Together Top Research, Professionals, Parents and Community Agencies, April 8-9 in Miami 4Health News:Children's Mental Health Conference Brings Together Top Research, Professionals, Parents and Community Agencies, April 8-9 in Miami 5Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 2Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 3Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 4Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 5Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 6Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 7Health News:VoiceNation Helps Non-Profits Gather Funding for Those in Need 2Health News:VoiceNation Helps Non-Profits Gather Funding for Those in Need 3Health News:Bosoley Solar Light Set to Bring Haiti Out of the Post-Earthquake Darkness 2Health News:Go with Your Gut and Boost your Immune System with America's Favorite Fruit 2Health News:Go with Your Gut and Boost your Immune System with America's Favorite Fruit 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: